- Could a patient population that is certainly not going to benefit from convalescent plasma transfusion be defined? – Do circulating viruses in donor blood represent a problem (in any scenario)? Would amotosalen eliminate this problem? Is the blood free of viruses when a SARS-Cov-2-specific PCR performed in nasopharingeal sample is negative? – Has the convalescent plasma dose been defined through a clinical trial? – How can the findings in some reports succeeding by using convalescent plasma therapy in patients showing significant levels of specific IgG anticoronavirus be explained? Should the presence of these antibodies eliminate a patient as a candidate for this therapy? / 请问能否界定哪些人群在(康复者)恢复期血浆疗法中不会有积极疗效?捐献的血浆中是否有携带病毒的问题?那么补骨酯衍生物(Amotosalen S-59)可以解决这个问题吗?如果一个患者的鼻咽采样中SARS-Cov-2核酸检测呈阴性，那他(她)的血液中就一定不含病毒了吗?恢复期血浆疗法剂量是否已经通过了相关的临床试验?请问如何解释那些关于在有显著水平的新冠特异性抗体IgG的病 人身上成功使用康复者恢复期 血浆疗法的报告?自身已带抗 体的病人应该从血浆疗法的接受者名单中除名吗?